Treatment benefits of upadacitinib based on disease severity, disease duration and number of prior biologics in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 3 trial data
In this medfyle
There is a need to understand UC treatment benefits in the context of disease severity, disease duration, and number of prior biologics used, to inform the optimal use of available therapies. This analysis evaluated the proportion of patients who achieved mucosal healing and complete symptom resolution with fatigue normalization with UPA treatment versus placebo in the context of these factors.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
This is a summary of a presentation given at the UEG Week 2023.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content.
©2023 Infomedica-Medfyle. All rights reserved.
